= Emerging. More than 5 years before clinical availability. (9.82%)
= Expected to be clinically available in 1 to 4 years. (12.95%)
= Clinically available now. (22.77%)
MSACL 2018 EU : Horro Pita

MSACL 2018 EU Abstract

Topic: Practical Training

Podium Presentation in the Ether on Thursday at 9:00 (Chair: Catarina Horro-Pita)

Where Did My Analyte Go? – coping with poor solubility and non-specific binding

Catarina Horro Pita (Presenter)
LGC, Drug Development Solutions

Presenter Bio(s): Dr Catarina Horro Pita possesses a BSc in Chemistry and Environmental Chemistry and a PhD in Synthetic Organic Chemistry. After concluding her PhD, she initiated her professional career as a Synthetic Chemist, prior to moving into Analytical Chemistry and Bioanalysis. She currently holds a position as a Principal Scientist in Drug Development Solutions at LGC, where she has been working for the past eleven years. During her time at LGC, she has worked both as a Study Director, which has given her extensive experience in managing GLP and GCP studies, and as a Technical Specialist, leading LC-MS/MS method development projects for the analysis of both xenobiotic compounds and small molecule biomarkers.

Authors: Catarina Horro Pita, Michael Wright
LGC, Drug Development Solutions


Poor solubility and non-specific binding can be insidious problems that are often overlooked during method development. These issues can result in costly and time-consuming batch failures during validation and, more importantly, the generation of inaccurate results during sample analysis. This training will describe in detail these issues, illustrate case studies and conclude with a workshop, where the audience will be asked to review ‘troublesome’ methods and suggest possible solutions.

Financial Disclosure

Board Memberno
IP Royaltyno

Planning to mention or discuss specific products or technology of the company(ies) listed above: